Get the app
US › Healthcare

Aldeyra The (ALDX)

US · Healthcare · Biotechnology

$0.63+2.89%
Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Net profit
$-3.76T
EPS
$-0.13
EPS estimate
$-0.11

EPS came in at -0.13 against a street estimate of -0.11 — a miss of 18.2%.

Key statistics

Market cap
$37.2M
Forward P/E
0.0
P/B
0.99
Book value
$0.63
EPS (TTM)
$-0.38
52-week high
$5.93
52-week low
$0.53
50-day MA
$1.09
200-day MA
$2.22
Beta
1.29

Analyst view

Analysts rate Aldeyra The a strong buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $6.60.

Shareholding

Insiders
3.60%
Institutions
60.71%

Largest institutional holders

FundStake
Knoll Capital Management LP9.08%
AQR Capital Management LLC6.22%
Kingdon Capital Management LLC4.40%
Vanguard Capital Management, LLC3.92%
D. E. Shaw & Co LP3.22%
Marshall Wace Asset Management Ltd2.50%
Jane Street Group LLC2.28%
BlackRock Inc2.08%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aldeyra The — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-11-07.